1cBio is an emerging biotech company based in the San Francisco Bay Area developing precision medicines for significant unmet needs. We focus on defined mechanisms of action which are validated in clinical practice, clinical trials, or preclinical models. Typically, our programs are geared to treat the disease and preemptively counter mechanisms for acquired or intrinsic resistance. We combine our core expertise in medicinal chemistry and translational sciences with thought partners in clinical and basic sciences to guide our innovation. Together with our network of research and development partners, our discovery platform is rapidly scalable and easily tailored to suit our current and future needs.

 

Our most advanced programs are a first-in-class oral small molecule to treat hypophosphatasia (HPP) and a potential best-in-class, selective PARP1 inhibitor. Through a partnership with Alesta Therapeutics, our HPP program entered clinical development in 2025, and initial Phase 1/2a clinical data in HPP patients are expected by H2 2026. PARP1 is the first program from our emerging portfolio of DDR-related programs which target both HR deficient and HR proficient tumors, in breast, prostate, ovarian and pancreatic cancers.